online | memorias.ioc.fiocruz.br Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(1): 38-43, February 2011 Hepatitis C virus (HCV) is estimated to infect around 170 million people worldwide and is one of the main causes of chronic liver failure (Brown & Gaglio 2003) . Combined treatment with interferon and ribavirin has been shown to interrupt fibrogenesis and can even reverse liver fibrosis when a sustained virological response (SVR) is obtained (Poynard et al. 2002) . Unfortunately, the response rates are low, especially among genotype 1 infected patients, older patients and patients with advanced liver fibrosis (Manns et al. 2001 , Lee et al. 2002 , Mihm et al. 2006 , Yamada et al. 2008 . Identifying appropriate candidates for treatment is desirable due to the high cost and potentially serious adverse effects of the current therapy.
Treatment for chronic hepatitis C (CHC) patients currently consists of a combination of interferon-α (IFN-α) and ribavirin for 24 or 48 weeks depending on the viral genotype (Strader et al. 2004 , de Araújo et al. 2007 ). Exogenous IFN-α acts similarly to its endogenous counterpart through induction of the IFN-stimulated genes responsible for establishing an antiviral state within the cell (Tilg 1997 , Feld & Hoofnagle 2005 . In addition to its direct antiviral activity, IFN-α strengthens both innate and adaptive immune responses through interactions with T lymphocytes, natural killer cells and dendritic cells (Tilg 1997) . Ribavirin, a guanosine-analogue, seems to work as an antiviral agent mainly by inducing HCV mutagenesis, which results in a lower replicative profile (Feld & Hoofnagle 2005) . Ribavirin also acts as an immunomodulator, enhancing type 1 T helper cell (Th)-1 cytokine secretion and altering the Th1/Th2 balance in favor of a Th1 response (Tam et al. 1999) .
SVRs [i.e., negative HCV qualitative polymerase chain reaction (PCR) 24 weeks after the end of treatment] are observed in approximately half of the treated patients and many factors, such as age, genotype, viral load and body weight, are related to treatment outcome (Manns et al. 2001 , Asselah et al. 2010 . The outcome of HCV treatment seems also to depend on the ability of host cellular immune responses to control viral replication. An early Th1 response is key for viral clearance during acute HCV infection (Guidotti & Chisari 2001 , Kamal et al. 2004 , Rehermann & Nascimbeni 2005 and an enhanced HCV-specific T-cell response is also associated with treatment response in chronically infected patients (Nelson et al. 1998 , Cramp et al. 2000 , Kamal et al. 2002 . Therefore, it is reasonable to suppose that pretreatment levels of cytokines, especially those involved in the Th1 response, may predict treatment outcome. Chemokines, a subgroup of small cytokines, are involved in leukocyte trafficking through a process called haptotaxis, in which leukocytes move towards higher concentrations of chemokines (Baggiolini et al. 1997 , Mackay 1997 , Luster 1998 , Kunkel 1999 , Gerard & Rollins 2001 , Ono et al. 2003 , Charo & Ransohoff 2006 . Chemokines are also involved in leukocyte activation, lymphocyte differentiation, regulation of the Th1/Th2 balance, angiogenesis and fibrogenesis (Charo & Ransohoff 2006) .
As the Th1 response is particularly involved in treatment responses of CHC patients, there is special interest in chemokines that are responsible for the recruitment of Th1 cells into the liver (Moura et al. 2009 ). The most important of these chemokines are CCL2 (monocyte chemotactic protein-1), CCL3 (macrophagic inflammatory protein 1 alpha), CCL4 (macrophagic inflammatory protein 1 beta), CCL5 (regulated upon activation, normal T cell expressed and secreted), CXCL9 (monokine induced by IFN-gamma) and CXCL10 (interferon-gamma inducible protein). The above mentioned CCL chemokines bind to C-C chemokine receptor type 5 while the CXCL chemokines bind to CXC chemokine receptor type 3 (Bonecchi et al. 1998 ). In the liver, chemokines are mainly produced by activated monocytes, Kupffer cells, endothelial cells and hepatocytes (Koziel 1999 , Apolinario Fernández de Sousa & García Monzón 2003 .
Another cytokine, tumor necrosis factor (TNF)-α, does not affect HCV RNA or protein synthesis and, therefore, does not seem to be directly involved in HCV clearance (Frese et al. 2003) . TNF synthesis is suppressed by IFN-α during HCV treatment (Abu-Khabar et al. 1992 ) and among patients treated with IFN-α and ribavirin, serum TNF-α levels significantly decreased at the end of treatment (Neuman et al. 2001) . Soluble TNF-α receptors (sTNF-R), which are released by activated neutrophils, mononuclear blood cells and fibroblasts (Porteu et al. 1991 , Lien et al. 1995 in response to mediators, such as interferon and TNF-α itself (Lantz et al. 1990 , Joyce et al. 1994 , Lien et al. 1995 , Tilg et al. 1995 , retain their ability to bind circulating TNF-α and are important in regulating its activity. These sTNF-R may contribute to the anti-inflammatory action of IFN-α. In hepatitis B virus infection, elevated serum levels of sTNF-R before interferon therapy were found to predict a successful response to treatment (Marinos et al. 1995) . In hepatitis C, the role of sTNF-R in predicting treatment responses is still not clear. Considering the characteristics of sTNF-R, including its greater stability in peripheral circulation, further studies are warranted to better understand the role of sTNF-R in predicting treatment responses.
We sought to investigate the association between peripheral pretreatment levels of several inflammatory markers, such as sTNF-R1 and sTNF-R2 and chemokines (CCL2, CCL3, CCL11, CCL24, CXCL9, CXCL10) and the virological response to IFN-α and ribavirin among patients with chronic HCV infection.
PATIENTS, MATERIALS AND METHODS
Patients -Between June 2005-December 2007, 41 consecutive patients with chronic hepatitis C infection who were submitted for treatment at the Orestes Diniz Center, a public university-based referral service for chronic hepatitis patients in Belo Horizonte, Minas Gerais, Brazil, were recruited for the study. All included patients were adults, had a positive anti-HCV antibody test [enzyme linked immunosorbent assay (ELISA)-3, Ortho Diagnostic Systems] and had HCV RNA that was detectable by PCR (AMPLICOR ® , Roche Molecular Systems) for more than six months. All patients had available liver biopsy samples with a length ≥ 1 cm and that contained at least five portal tracts, as evaluated by an independent, experienced liver pathologist using the METAVIR scoring system (Bedossa & Poynard 1996) . Patients were also negative for auto-antibodies (ANA, anti-mitochondria, anti-smooth muscle) and had negative results for Schistosoma mansoni ova on three stool samples. The mean age of the included patients was 44.4 (± 11.11) years and 23 (56.1%) were male. Moderate/severe liver inflammatory activity was present in 20 (48.8%) patients, moderate/severe liver fibrosis (METAVIR F ≥ 2) was present in 28 (68.3%) and cirrhosis (METAVIR F4) was present in 10 (24.4%). Patients were excluded if they had previously used IFN-α with or without ribavirin or had any of the following: coinfection with HBV or HIV, chronic use of steroids or immunosuppressant drugs or renal failure. Socio-demographic, clinical and laboratory data were obtained through chart review and patient interview.
Treatment of CHC virus infection -
The study treatment protocol followed Brazilian national guidelines for treatment of HCV infection that were available at the time (MS 2002) . According to the guidelines, genotype 1-infected patients received a 48-week regimen of subcutaneous peg-IFN-α [either peg-IFN-α-2a (180 mcg/week) or peg-IFN-α-2b (1.5 mcg/kg/week)], at the physician's discretion) plus weight-based oral ribavirin (1000 mg/day for patients weighing less than 75 kg and 1250 mg/day for those weighting 75 kg or more). Patients with genotype 2 or 3 HCV infection received a 24-week regimen of subcutaneous IFN-α (3 mega units 3 times a week) plus the same weight-based oral ribavirin mentioned previously.
To assess early virological response (EVR), all genotype 1 patients had their HCV RNA quantified in plasma samples before treatment and at treatment week 12 using a PCR assay (AMPLICOR ® , Roche Molecular Systems, with detection limits of 600 IU/mL and 850,000 IU/mL). Those patients without an EVR (i.e., without a drop in viral load of at least 2 logs at treatment week 12) had their treatment interrupted. Patients with genotypes 2 and 3 were treated for 24 weeks with no interim quantitative assessment of HCV viral load.
Chemokines and sTNF-R quantification -Plasma samples were taken from patients before starting therapy, at treatment week 12 (only for patients with HCV genotype 1 infection) and 24 weeks after treatment completion and were frozen at -70ºC until measurements were performed. For chemokine analysis, plasma samples were thawed and excess proteins, mainly albumin, were removed by acid ⁄salt precipitation (Sousa-Pereira et al. 2006) . Briefly, an equal volume of plasma and 1.2% trifluoroacetic acid ⁄1.35 M NaCl were mixed and left at room temperature for 10 min. Samples were then centrifuged for 5 min at 3000 g and the supernatants were adjusted for salt content (0.14 M sodium chloride and 0.01 M sodium phosphate) and pH (7.4) for the determination of chemokine and sTNF-R levels. For sTNF-R measurement, samples were diluted in phosphate buffered saline.
Plasma concentrations of chemokines and sTNF-R were measured using sandwich ELISA kits for CCL2, CCL3, CCL11, CCL24, CXCL9, CXCL10, sTNF-R1 and sTNF-R2 (DuoSet, R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. The detection limits were 10 pg/mL for chemokines and 5 pg/mL for sTNF-R. All samples were assayed in duplicate on the same plate.
Statistical analysis -Non-parametric analyses were performed using the Kruskal-Wallis test to compare median levels of soluble inflammatory markers between patients with or without SVRs. For those with genotype 1 infection, a comparison was also made between those with and without EVR. The receiver operator characteristic curve was used to evaluate the accuracy of soluble inflammatory markers to predict a virological response. The outcomes assessed were both EVR and SVR for patients with genotype 1 infection, whereas only the SVR was assessed for those with genotype 2 or 3 infection.
Statistical analysis was performed using the SPSS software package (version 12.0, SPSS Inc, Chicago, IL, USA). All reported p values are 2-sided and statistical significance was set at p < 0.05.
Ethical approval -The study was approved by ethical committees at the Federal University of Minas Gerais and was performed in accordance with the ethical standards outlined in the Declaration of Helsinki.
RESULTS
Of the 41 patients included in the study, 29 (70.7%) had a genotype 1 infection, 29 (70.7%) had alanine aminotransferase greater than 1.5 times the normal upper limit and 28 (68.3%) had moderate/severe liver fibrosis, including 10 (24.4%) with cirrhosis. Pretreatment HCV viral load was assessed among those with genotype 1 infections and 16 (57.1%) had levels greater than 600,000 IU/mL. Of patients with genotype 1 infection, eight were treated with peg-IFN-α-2a and 21 with peg-IFN-α-2b and both treatments included weight-based ribavirin. All patients with genotype 2 or 3 infections were treated with conventional IFN-α combined with weight-based ribavirin. EVR was observed in 69% of patients infected with genotype 1. Global SVR was 55.3% and was greater among those infected with genotype 2 compared to those infected with genotype 1 or 3 (100%, 57.1% and 46.2%, respectively). Three patients were excluded from the SVR analysis: two abandoned treatment after week 12 and one interrupted treatment at week 16 due to severe anemia.
Analysis of the association between pretreatment levels of soluble inflammatory markers and virological response showed that elevated CXCL10 levels were associated with a lack of both EVR (p = 0.011) ( Table I) and SVR (p = 0.045) (Figs 1, 2, Tables I, II) . The accuracy of plasma CXCL10 levels to predict a lack of EVR was 0.79 [confidence interval (CI) 95%: 0.59-0.99], with a sensitivity of 78% and 65% specificity of lack of EVR using 220 pg/mL as the cut-off point. Using a lower cut-off point of 150 pg/mL and an upper cut-off level of 450 pg/mL for predicting EVR yielded a positive predictive level and a negative predictive level of 85.7% and 71.4%, respectively; in this setting, 15 (51.7%) patients presented with CXCL10 plasma levels between 150-450 pg/mL and could not be classified. The accuracy of CXCL10 plasma levels was lower for predicting SVR (0.69; CI 95%: 0.51-0.87). Applying the same cut-off values used in the evaluation of EVR (i.e., 150 pg/mL and 450 pg/mL), positive and negative predictive values for achieving SVR were 78.6% and 66.7%, respectively. Fifteen (39.5%) patients presented with CXCL10 plasma levels between 150-450 pg/mL and could not be classified using these cut-off points.
Only four patients had CXCL10 plasma levels greater than 600 pg/mL. Among this small group of patients, global SVR was 25% and the only responder had a genotype 2 infection.
The other soluble inflammatory markers assessed were not associated with therapeutic response (Tables I, II) .
DISCUSSION
We showed that pretreatment plasma levels of CXCL10 were inversely correlated with response to treatment with IFN-α and ribavirin in patients with hepatitis C infection.
Although this finding has been reported by other authors (Narumi et al. 1997 , Apolinario et al. 2004 , Butera et al. 2005 , Diago et al. 2006 , their results were based on the analysis of patients treated in the well-controlled context of clinical trials; our study strengthens the evidence for an association between CXCL10 levels and virological response among patients with CHC infection by showing an elevated negative predictive value in a real-life clinical setting.
In addition, our study did not show an association between plasma levels of the CC chemokines evaluated (CCL2, CCL3, CCL11, CCL24) and of sTNF-R with virological response. We did not find studies in the literature evaluating the association between peripheral levels of these other inflammatory markers and treatment response among patients with CHC. Apolinario et al. (2004) were the first to point out the association between serum levels of CXCL10 and therapeutic response. Accuracy of CXCL10 in predicting lack of SVR was 0.74, which is slightly higher than that found in our study (0.69; CI 95%: 0.51-0.87). Using a cut-off point of 299 pg/mL for predicting lack of virological response, Apolinario et al. (2004) found a sensitivity and specificity of 80% and 63%, respectively, which was very similar to that found in our study (78% and 65%, respectively). Lagging et al. (2006) stratified patients into three groups according to pretreatment CXCL10 levels (0-150 pg/mL; 150-600 pg/mL; > 600 pg/mL). Levels greater than 600 pg/mL had a negative predictive value for SVR of 79%. In a subanalysis including only difficult to treat patients (i.e., elevated body mass index or high viral load) with high CXCL10 levels, none of the seven patients achieved SVR. In our study, of the four patients with levels greater than 600 pg/mL, only one genotype 2 infected patient achieved SVR.
Different theories have been presented to explain the relationship between elevated levels of CXCL10 and poor response rates. High peripheral levels of CXCL10 could impair local CCL5 or CXCL10 gradient signaling (Butera et al. 2005) or could downregulate CXCR5 receptors in circulating CTL (Larrubia et al. 2007 ). Other authors (Diago et al. 2006) propose that elevated CXCL10 levels may result in an accumulation of effector T cells in the liver and the selective pressure imposed by this accumulation may foster outgrowth of immune escape HCV mutants that would be more difficult to eradicate with combined therapy (Diago et al. 2006) . The observed association between CXCL10 levels and therapeutic response was not mediated by liver histological changes, as plasma levels of this chemokine were not associated with liver inflammatory activity or fibrosis in a subanalysis of the dataset (Moura et al. 2010) .
CXCL9, which binds the same chemokine receptor as CXCL10 (i.e., CXC3), did not show an association with virological response in our study, in accordance with findings from a previous study conducted by Butera et al. (2005) . Although acting in similar cells, a different regulation mechanism for this chemokine may explain this apparent inconsistency.
The small number of treated patients in our study limits the interpretation of the lack of an association between some of the inflammatory markers evaluated and virological response. Another limitation of our study was the evaluation of EVR only for genotype 1 infected patients; therefore, the association found between CXCL10 levels and EVR cannot be extrapolated to patients infected by other HCV genotypes.
In summary, we have shown that pretreatment plasma levels of CXCL10 were associated with virological response among patients with CHC infection. Due to the high negative predictive value of elevated pretreatment CXCL10 levels, their assessment may be useful in the evaluation of potential candidates for therapy with interferon and ribavirin.
